Elmed Life Sciences Raises $2.7 Mn to Scale Probiotic Innovation and Microbiome Research

Probiotics manufacturer Elmed Life Sciences has raised $2.7 million (₹25.4 crore) in its Series A funding round, led by NABVENTURES through its AgriSURE Fund (Agri Fund for Startups & Rural Enterprises). The funding marks a significant step forward for the company as it strengthens its position in the rapidly growing microbiome and probiotics space.

Founded in 2018 by Pruthivin Reddy Madduri and Nikhil Konkathi, Elmed Life Sciences focuses on delivering advanced probiotic solutions through contract manufacturing and research-driven services. The company works with leading global healthcare and agri-biotech firms, including Hetero Healthcare, Wallace Pharmaceuticals, and others.

The freshly raised capital will be used to expand production capacity and accelerate microbiome-focused research and development. This strategic investment aligns with the increasing global demand for probiotic-based solutions across healthcare, agriculture, and nutrition sectors.

Microbiome-based solutions are emerging as a transformational approach in modern science, focusing on balancing microorganisms such as bacteria, fungi, and viruses within a host organism. These solutions are designed to restore ecological balance, enhance immunity, and improve overall resilience, making them highly relevant across both human health and agricultural ecosystems.

Elmed Life Sciences is positioning itself at the forefront of this innovation wave by combining scientific expertise with scalable manufacturing capabilities. Its offerings enable partners to develop customized probiotic solutions tailored to specific use cases, whether in human health, animal nutrition, or crop science.

The probiotics and microbiome market is witnessing rapid growth globally, driven by rising awareness about gut health, preventive healthcare, and sustainable agricultural practices. As industries shift towards more natural and science-backed solutions, companies like Elmed are playing a critical role in shaping the future of biotechnology.

With strong backing from NABVENTURES and a clear focus on innovation, Elmed Life Sciences aims to strengthen its R&D pipeline and expand its global footprint. The company’s ability to serve diverse sectors, from pharmaceuticals to agri-biotech, gives it a unique advantage in a highly competitive market.

As it scales operations and deepens its research capabilities, Elmed is well-positioned to become a key player in the global probiotics ecosystem, driving the adoption of microbiome-based solutions that promote healthier lives and more sustainable environments.